Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07264283Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Role: lead

NCT07173803Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform

Role: lead

NCT07217665Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Role: lead

NCT03277573Phase 1Completed

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Role: lead

NCT02422485Phase 1Completed

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

Role: lead

All 5 trials loaded